Cue Health launches Cue Care™ nationwide to provide same-day home testing service for COVID-19

SAN DIEGO, August 29, 2022 /PRNewswire/ — Cue Health Inc. (Nasdaq: HLTH), a health technology company that places diagnostic information at the center of care, today announced the national launch of Cue Care™, its screening test at home the same day. treatment solution. Patients in any of 50 states who test positive using Cue’s COVID-19 tests can now use the Cue Health app to:

  1. Consult virtually and on demand with a healthcare professional about their test result;
  2. Obtain an electronic prescription – if medically indicated – for a drug to treat the virus; and
  3. Have the medications delivered – usually within hours* – easily and safely to your home or the medications will be made available for pick up at their local pharmacy.

In a few weeks, Cue Health plans to expand this new service to patients who test positive for COVID-19, including home antigen testing. The Cue Care antiviral delivery service costs between $79 and $99 and includes a televisit with a medical professional and delivery of a drug, the cost of which is currently covered by the US Department of Health and Human Services. social (HHS). According to HHS, early treatment for COVID-19 can help improve patient outcomes, reduce hospitalizations and even save lives.

“Early diagnosis and treatment have been shown to lead to better health outcomes, which is why we’re proud to offer timely testing and treatment in the Cue Health app,” Ayub said. Khattak, president and CEO of Cue Health. “Cue Care is addressing the need for convenient delivery of COVID-19 treatment today, and this capability will support our expanding pipeline of future diagnostic tests.

Current and future testing capabilities

While Cue Care is aimed at COVID-19 patients today, it should apply to a wide range of diagnostic tests in Cue’s pipeline, especially those for which specific treatments are available. For example, if someone tests positive for the flu, they will be able to use Cue Care to connect with a healthcare professional and, if eligible, have a flu antiviral delivered the same day, all within Cue Health app. Cue Care should treat other respiratory infections, such as strep throat and respiratory syncytial virus (RSV), as well as sexually transmitted infections, such as chlamydia and gonorrhea.

Cue offers the most accurate home COVID-19 test**, delivering results in 20 minutes to connected mobile devices. It detects all known COVID-19 variants of concern in people with and without symptoms. Cue is used at home, at points of service, and by world-class organizations across the country, including Johns Hopkins Medicine, Mayo Clinic, Google, the National Basketball Association, and Major League Baseball, among others.

*Antiviral medications prescribed by independent healthcare professionals through Cue Care are subject to patient availability and eligibility. Cue Health Inc. is not affiliated with any pharmaceutical manufacturer.

**Precision Claim #1 based on comparison of clinical study results submitted to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization for Cue and other molecular tests at residence.

About Cue Health

Cue Health (Nasdaq: HLTH) is a health technology company that makes it easier for people to access health information and places diagnostic information at the center of care. Cue Health empowers people to manage their health with real-time, actionable, and connected health information, giving individuals and their healthcare providers easy access to lab-quality diagnostics anywhere, anytime , in a device that fits in the palm of your hand. Cue Health’s first COVID-19 test was the first molecular diagnostic test cleared by the FDA for home and over-the-counter use without a prescription or medical supervision. Outside the United States, Cue Health has received CE Mark in the European Union, Interim Prescription Clearance from Health Canada, Regulatory Approval from the Central Drugs Standard Control Organization of India, and Clearance PSAR from the Health Sciences Authority of Singapore. Cue was founded in 2010 and is based in San Diego. For more information, please visit

Forward-looking statementsThe statements in this press release regarding future expectations, plans and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements”. The words, but not limited to, “anticipate”, “believe”, “continue”, “could”, “estimate”, “expect”, “intend”, “may”, “plan “, “potential”, “predict”, “project”, “should”, “target”, “will”, “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identification words or similar words. Actual results may differ materially from those indicated by these forward-looking statements due to a variety of important factors, including those related to the expected future menu of diagnostic tests and the factors discussed in the “Risk Factors” section of Cue’s annual report on Form 10.-K for the fiscal year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 filed with the SEC on August 10, 2022. All forward-looking statements contained in this release releases are based on the current expectations of Cue’s management team and speak only as of the date hereof, and Cue specifically disclaims any obligation to update any forward-looking statements, whether as a result of new information , future events or otherwise.Cue’s COVID-19 tests have not been approved or cleared by the FDA; but have been cleared by the FDA and under an Emergency Use Authorization (EUA). These products have been authorized only for the detection of SARS-CoV-2 nucleic acid, and not for other viruses or pathogens. Emergency use of these products is authorized only for the duration of the declaration of the existence of circumstances justifying the authorization of emergency use of in vitro diagnostics for the detection and/or diagnosis of COVID -19 under Section 564(b)(1) of the Federal Food, Drug and Cosmetic Act, 21 USC § 360bbb-3(b)(1), unless the statement is terminated or the authorization is revoked sooner.

(PRNewsfoto/Cue Health Inc.)

Quote View original content to download multimedia: -treatment-service-for-covid-19-301613695.html

SOURCE Cue Health Inc.

Comments are closed.